Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 6/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24255781 | 0.88 | AR (0.33) | ARGSK3BDYRK1AMAPK14TTK | |
| SCHEMBL27078324 | 0.77 | CYP17A1 (0.38) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6133253 | 0.76 | MAPK14 (0.40) | GSK3BDYRK1AMAPK14CNR2ITGA4 | |
| SCHEMBL6133366 | 0.75 | BRD9 (0.35) | GSK3BDYRK1AMAPK14CNR2ITGA4 | |
| SCHEMBL6133365 | 0.75 | BRD9 (0.35) | GSK3BDYRK1AMAPK14CNR2ITGA4 | |
| SCHEMBL28847399 | 0.74 | MAPK14 (0.35) | GSK3BDYRK1AMAPK14CNR2ITGA4 | |
| SCHEMBL20262308 | 0.71 | MAPK14 (0.37) | GSK3BDYRK1AMAPK14CNR2ITGA4 | |
| SCHEMBL20262310 | 0.71 | MAPK14 (0.37) | GSK3BDYRK1AMAPK14CNR2ITGA4 | |
| SCHEMBL25405967 | 0.70 | CA12 (0.35) | — | |
| SCHEMBL2173526 | 0.70 | MAPK1 (0.41) | GSK3BDYRK1AMAPK14CNR2BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | KCNJ5, IL5, CYP3A5 | AR 2796/4885GSK3B 1804/4885DYRK1A 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.